Aurinia Pharma U.S., Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$13.0M
Doctors Paid
11,069
Transactions
56,830
2024 Total
$3.6M
Payment Breakdown by Category
Research$6.1M (47.2%)
Food & Beverage$1.5M (11.2%)
Travel$544,155 (4.2%)
Consulting$190,528 (1.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6.1M | 678 | 47.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4.0M | 1,937 | 30.8% |
| Food and Beverage | $1.5M | 49,896 | 11.2% |
| Travel and Lodging | $544,155 | 2,121 | 4.2% |
| Honoraria | $319,342 | 96 | 2.5% |
| Grant | $218,134 | 14 | 1.7% |
| Consulting Fee | $190,528 | 48 | 1.5% |
| Space rental or facility fees (teaching hospital only) | $67,812 | 11 | 0.5% |
| Education | $38,152 | 2,028 | 0.3% |
| Charitable Contribution | $25,000 | 1 | 0.2% |
Payments by Type
General
$6.8M
56,152 transactions
Research
$6.1M
678 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| LUPKYNIS Registry Study | $1.7M | 0 | 476 |
| A double-blind, randomized, placebo-controlled, single and multiple ascending dose (SAD and MAD) study to investigate the safety, tolerability and pharmacokinetics of AUR200 in healthy volunteers | $1.1M | 0 | 7 |
| A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, CONTINUATION STUDY COMPARING THE LONG-TERM SAFETY AND EFFICACY OF VOCLOSPORIN (23.7 MG TWICE DAILY) WITH PLACEBO IN SUBJECTS WITH LUPUS NEPHRITIS | $875,485 | 0 | 27 |
| 496599-Tissue localization of Cyclosporine, Voclosporine a | $573,529 | 0 | 7 |
| Effect of voclosporin on renal vessels, immune cell adherence and proximal convoluted tubules in microphysiological systems | $319,729 | 0 | 8 |
| A RANDOMIZED, CONTROLLED DOUBLE-BLIND STUDY COMPARING THE EFFICACY AND SAFETY OF VOCLOSPORIN (23.7 MG TWICE DAILY) WITH PLACEBO IN ACHIEVING RENAL RESPONSE IN SUBJECTS WITH ACTIVE LUPUS NEPHRITIS | $305,492 | 0 | 50 |
| Voclosporin in Adolescents With Lupus Nephritis (VOCAL) | $278,776 | 0 | 35 |
| AURINIA RENAL ASSESSMENTS 2: AURINIA RENAL RESPONSE IN LUPUS WITH VOCLOSPORIN (AURORA2) | $263,823 | 0 | 40 |
| 21-608 Molecular targets of Voclosporin in kidney podocytes and the effect on the actin cytoskeleton | $199,930 | 0 | 2 |
| 2904 PK study of Voclosporin and Tacrolimus when combined with Rifampin or Ketoconazole in CD-1 mouse models | $140,000 | 0 | 2 |
| Fornoni-Voclosporin in Alport Syndrome | $124,846 | 0 | 8 |
| Effect of voclosporin (VCS) on diabetes in the streptozotocin-induced type 1 diabetes | $101,424 | 0 | 4 |
| Long-Term Voclosporin Treatment in Adolescent Subjects With Lupus Nephritis | $73,559 | 0 | 3 |
| 498549-Voclosporin and Lipids Contract | $37,799 | 0 | 1 |
| 1923 Voclosporin in Alport Syndrome (PI Dr. Alessia Fornoni) | $36,275 | 0 | 4 |
| 1385 PI: Smoyer, Dr. William E. - Voclosporin effect on molecular pathways and lipids in nephrotic syndrome | $31,785 | 0 | 1 |
| A DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE ESCALATION STUDY TO ASSESS THE EFFICACY, SAFETY AND PHARMACOKINETICS OF VOCLOSPORIN IN ADOLESCENTS WITH LUPUS NEPHRITIS | $17,964 | 0 | 1 |
| Drug-Drug Interaction Study to Investigate Effects of Voclosporin on Pharmacokinetics of Simvastatin (Statin-DDI) | $2,737 | 0 | 2 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| German Hernandez, M.d, M.D | Internal Medicine | El Paso, TX | $292,745 | $0 |
| Tina Kochar, Md, MD | Internal Medicine | Galveston, TX | $224,946 | $0 |
| Dr. Jorge Larranaga, Md, MD | Nephrology | Kissimmee, FL | $218,758 | $0 |
| Abdul Abdellatif, M.d, M.D | Internal Medicine | Webster, TX | $182,921 | $0 |
| Dr. Sreedhara Alla, M.d, M.D | Internal Medicine | Shreveport, LA | $148,438 | $0 |
| Dr. Gerald Appel, M.d, M.D | Nephrology | New York, NY | $140,837 | $0 |
| Michael Aaronson, M.d, M.D | Nephrology | Lincoln, NE | $134,331 | $0 |
| Joshua Kaplan, M.d, M.D | Nephrology | Newark, NJ | $128,249 | $0 |
| Dr. Jose Morfin, M.d, M.D | Nephrology | Sacramento, CA | $125,597 | $0 |
| Sanjay Chabra, D.o, D.O | Rheumatology | El Paso, TX | $121,206 | $0 |
| Dhiman Basu, Md, MD | Internal Medicine | Colleyville, TX | $114,313 | $0 |
| Dr. Mohammad Kamgar, M.d, M.D | Internal Medicine | Los Angeles, CA | $105,992 | $0 |
| Dr. Alvin Wells, Md, MD | Rheumatology | Destin, FL | $103,447 | $0 |
| Anne Winkler, Md, MD | Rheumatology | Carthage, MO | $98,568 | $0 |
| Andrew Lazar, Md, MD | Nephrology | Beachwood, OH | $96,846 | $0 |
| Dr. James Tumlin, M.d, M.D | Nephrology | Lawrenceville, GA | $96,723 | $0 |
| Laura Geraldino Pardilla, M.d, M.D | Internal Medicine | New York, NY | $95,996 | $0 |
| Dr. Mohammed Ahmed, D.o, D.O | Internal Medicine | Bolingbrook, IL | $94,605 | $0 |
| Leanna Wise, M.d, M.D | Rheumatology | Los Angeles, CA | $71,748 | $0 |
| Dr. Ramy Hanna, M.d, M.D | Nephrology | Orange, CA | $71,526 | $0 |
| Howard Belmont, Md, MD | Rheumatology | New York, NY | $70,230 | $0 |
| Petros Efthimiou, Md, MD | Rheumatology | New York, NY | $69,277 | $0 |
| Dr. Robin Mcgarry, M.d, M.D | Psychiatry | New York, NY | $69,250 | $0 |
| Elizabeth Clayton, Md, MD | Rheumatology | Easton, MD | $64,488 | $0 |
| Sheetal Desai, Md, MD | Rheumatology | Orange, CA | $62,848 | $0 |
About Aurinia Pharma U.S., Inc.
Aurinia Pharma U.S., Inc. has made $13.0M in payments to 11,069 healthcare providers, recorded across 56,830 transactions in the CMS Open Payments database. In 2024, the company paid $3.6M. The top product by payment volume is LUPKYNIS ($10.5M).
Payments were distributed across 135 medical specialties. The top specialty by payment amount is Nephrology ($1.9M to 2,968 doctors).
Payment categories include: Food & Beverage ($1.5M), Consulting ($190,528), Research ($6.1M), Travel & Lodging ($544,155).
Aurinia Pharma U.S., Inc. is associated with 1 products in the CMS Open Payments database.